When does the Pfizer Premarin patent expire?

The Pfizer Premarin patent has been the subject of ongoing litigation and challenges. According to DrugPatentWatch.com [1], the patent for Premarin (conjugated estrogens) held by Pfizer expires in 2024. However, generic versions of the drug have been available since 2015 due to a settlement agreement between Pfizer and several generic manufacturers.

What led to the patent challenges?

In 2005, the FDA approved generic versions of Premarin, but Pfizer successfully appealed the decision, arguing that the generics were not equivalent to the brand-name product. However, in 2007, a federal appeals court ruled in favor of the generic manufacturers, upholding the FDA's approval of the generics.

Why is this patent significant?

The Premarin patent has been the subject of much controversy due to the high cost of the medication and the lack of generic alternatives. The patent challenges have allowed generic manufacturers to enter the market, potentially reducing the cost of the medication for patients.

How has the patent impacted patients?

The long delay in the availability of generic versions of Premarin has had a significant impact on patients. Prior to the settlement agreement, patients faced high costs for the medication, which often exceeded $1,000 per month. The availability of generic versions has helped to reduce these costs, making the medication more accessible to patients.

What are the implications for Pfizer?

The expiration of the Premarin patent in 2024 will likely significantly impact Pfizer's revenue in the coming years. The company will need to adapt to the increased competition from generic manufacturers and potentially develop new products to offset the lost revenue.

What's next for Premarin?

As the patent expires, Pfizer may face increased competition from generic manufacturers, which could further reduce the cost of the medication for patients. However, the company may also have opportunities to develop new products or enter new markets, potentially offsetting the lost revenue.

When does exclusivity expire?

The exclusivity period for Premarin expired in 2015, allowing generic manufacturers to enter the market. However, the patent challenges led to a settlement agreement, which allowed Pfizer to maintain its market position until 2024.

Can biosimilars enter before patent expiry?

Biosimilars, which are highly similar copies of biologic drugs, can enter the market at any time. However, the availability of biosimilars is dependent on the approval of the FDA and may be subject to patent challenges.

Sources:

[1] DrugPatentWatch.com. (n.d.). Premarin (Conjugated Estrogens) Patents. Retrieved from https://www.drugpatentwatch.com/patents/1556

Cited sources:

DrugPatentWatch.com.